Exemestane experience in breast cancer treatment

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 3-6, 1997, Pages 151-155

  Lonning P E ^a   Paridaens, R ^b   Thurlimann B ^c   Piscitelli, G ^d   Di Salle, E ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; EXEMESTANE; MEGESTROL ACETATE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ESTROGEN BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; RADIOIMMUNOASSAY;

EID: 0031120020     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00216-6     Document Type: Conference Paper

References (32)

1. Miller W.R. Aromatase inhibition in the treatment of advanced breast cancer. Cancer Treat. Rev. 16:1989;83-93.
2. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Tsai-Morris C.-H., Marcotte P.A., Robinson C.H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids. 38:1981;693-702.
3. Thürlimann B., Beretta K., Bacchi M., Goldhirsch A., Jungi W.F., Castiglione M., Cavalli F., Senn H.J., Fey M. First line fadrozole HCl (CGS 16949A) versus tamoxifen (TAM) in advanced breast cancer: prospective randomised study SAKK 20/88. ASCO Abstr. 90:1995;98.
4. Iveson T.J., Smith I.E., Ahern J., Smithers D.A., Trunet P.F., Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53:1993;266-270.
5. Johnston S.R.D., Smith I.E., Doody D., Jacobs S., Robertshaw H., Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 54:1994;5875-5881.
6. Dowsett M., Cunningham D.C., Stein R.C., Evans S., Dehennin L., Hedley A., Coombes R.C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49:1989;1306-1312.
7. Dowsett M., Mehta A., King N., Smith I.E., Powles T.J., Stein R.C., Coombes R.C. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur. J. Cancer. 28:1992;415-420.
8. MacNeill F.A., Jacobs S., Dowsett M., Lønning P.E., Powles T.J. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in postmenopausal breast cancer patients. Cancer Chemother. Pharmacol. 36:1995;249-254.
9. di Salle E., Briatico G., Giudici D., Ornati G., Zaccheo T., Buzzetti F., Nesi M., Panzeri A. Novel aromatase and 5alpha-reductase inhibitors. J. Steroid Biochem. Molec. Biol. 49:1994;289-294.
10. di Salle E., Giudici D., Briatico G., Ornati G. Novel irreversible aromatase inhibitors. Ann. N.Y. Acad. Sci. 595:1990;357-367.
11. Buzzetti F., di Salle E., Longo A., Briatico G. Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). Steroids. 58:1993;527-532.
12. Giudici D., Ornati G., Briatico G., Buzzetti F., Lombardi P., di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem. 30:1988;391-394.
13. di Salle E., Giudici D., Ornati G., Briatico G., D'Alessio R., Villa V., Lombardi P. 4-Aminoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J. Steroid Biochem. Molec. Biol. 37:1990;369-374.
14. Zaccheo T., di Salle E. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother. Pharmacol. 25:1989;95-98.
15. Zaccheo T., Giudici D., Ornati G., Panzeri A., di Salle E. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur. J. Cancer. 27:1991;1145-1150.
16. Evans T.R.J., di Salle E., Ornati G., Lassus M., Strolin Benedetti M., Pianezzola E., Coombes R.C. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 52:1992;5933-5939.
17. Zilembo N., Noberasco C., Bajetta E., Martinetti A., Mariani L., Orefice S., Buzzoni R., Bartolomeo M.D., Leo A.D., Laffranchi A., di Salle E. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer. 72:1995;1007-1012.
18. Johannessen D. C., Engan T., di Salle E., Zurlo M. G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S. and Lønning P. E.: Endocrine and clinical effects of exemestane (PNU 155071) a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients; Phase I study. Clin. Cancer Res., in press.
19. di Salle E., Ornati G., Paridaens R., Coombes R.C., Lobelle J.P., Zurlo M.G. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). Motta M., Serio M. Sex Hormones and Antihormones in Endocrine-dependent Pathology; Basic and Clinical Aspects. 1994;303-310 Elsevier Science, Amsterdam.
20. Cocchiara G., Allievi C., Berardi A., Zugnoni P., Strolin Benedetti M., Dostert P. Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers. J. Endocr. Invest. 17:(Suppl. 1):1994;78.
21. Santen R.J., Samojlik E., Wells S.A. Resistance of the ovary to blockade of aromatisation with aminoglutethimide. J. Clin. Endocr. Metab. 51:1980;473-477.
22. Dowsett M., Stein R.C., Coombes R.C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Molec. Biol. 43:1992;155-159.
23. Harris A.L., Dowsett M., Jeffcoate S.L., McKinna J.A., Morgan M., Smith I.E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocr. Metab. 55:1982;718-722.
24. Lønning P.E., Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit. Rev. Oncol./Haematol. 21:1995;158-193.
25. Jonat W., Howell A., Blomqvist C., Eiermann W., Winblad G., Tyrrell C., Mauriac L., Roche H., Lundgren S., Hellmund R., Azab M. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer. 32A:1996;404-412.
26. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Chaudri H.A., Homberger U. Double-blind trial in post-menopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effects and superiority of 2.5 mg letrozole over megestrol acetate (MA) Abstr. 64. ASCO Abstr. 15:1996;100.
27. Elomaa I., Blomquist C., Rissanen P. Aminoglutethimide as second-line therapy in advanced breast cancer. Breast Cancer Res. Treat. 7:1986;S51-S54.
28. Geisler J., Johannessen D.C., Anker G., Lønning P.E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur. J. Cancer. 32:1996;789-792.
29. Zambetti M., Brambilla C., Tancini G., Bonadonna G. Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. Tumori. 73:1987;369-373.
30. Iveson T.J., Ahearn J., Smith I.E. Response to third-line endocrine treatment for advanced breast cancer. Eur. J. Cancer. 29A:1993;572-574.
31. Garcia-Giralt E., Ayme Y., Carton M., Daban A., Delozier T., Fargeot P., Fumoleau P., Gorins A., Guerin D., Guerin R., Maillart P., Mauriac L., May-Levin F., Metz R., Namer M., Olivier J.P., Pommatau E., Pouillart P., Pujade-Lauraine E., Rouesse J., Serrou B., Vitse M., Zylberait D. Second and third line hormontherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medrozyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res. Treat. 24:1992;139-145.
32. Murray R., Pitt P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat. 35:1995;249-253.